Literature DB >> 18343072

Extracellular gadolinium contrast agents: differences in stability.

S K Morcos1.   

Abstract

Extracellular gadolinium contrast agents (Gd-CA) are either linear or macrocyclic chelates available as ionic or non-ionic preparations. The molecular structure whether cyclic or linear and ionicity determines the stability of Gd-CA. Linear chelates are flexible open chains which do not offer a strong binding to Gd(3+). In contrast, the macrocyclic chelates offer a strong binding to Gd(3+) by the virtue of being preorganized rigid rings of almost optimal size to cage the gadolinium atom. Non-ionic preparations are also less stable in comparison to the ionic ones as the binding between Gd(3+) with the negatively charged carboxyl groups is stronger in comparison to that with amides or alcohol in the non-ionic preparations. According to stability constants and kinetic measurements, the most stable Gd-CM is the ionic-macrocyclic chelate Gd-DOTA and the least stable agents are the non-ionic linear chelates gadodiamide and gadoversetamide. In vivo data confirmed the low stability of non-ionic linear chelates but no significant difference was observed amongst the macrocyclic agents whether ionic (Gd-DOTA) or non-ionic such as Gd-HP-DO3A and Gd-BT-DO3A. The stability of Gd-CA seems to be an important factor in the pathogenesis of the serious complication of nephrogenic systemic fibrosis. Gd-CA of low stability are likely to undergo transmetallation and release free Gd ions that deposit in tissue and attract circulating fibrocytes to initiate the process of fibrosis. No cases of NSF have been observed so far after the exclusive use of the stable macrocyclic Gd-CA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343072     DOI: 10.1016/j.ejrad.2008.01.025

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  46 in total

Review 1.  Gadolinium-based contrast agents in pediatric magnetic resonance imaging.

Authors:  Eric M Gale; Peter Caravan; Anil G Rao; Robert J McDonald; Matthew Winfeld; Robert J Fleck; Michael S Gee
Journal:  Pediatr Radiol       Date:  2017-04-13

2.  Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent.

Authors:  Narasimharao Bhagavathula; Marissa DaSilva; Muhammad N Aslam; Michael K Dame; Roscoe L Warner; Yiru Xu; Gary J Fisher; Kent J Johnson; Richard Swartz; James Varani
Journal:  Invest Radiol       Date:  2009-08       Impact factor: 6.016

Review 3.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

4.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

5.  Effect of lanthanide ions on dynamic nuclear polarization enhancement and liquid-state T1 relaxation.

Authors:  Jeremy W Gordon; Sean B Fain; Ian J Rowland
Journal:  Magn Reson Med       Date:  2012-02-24       Impact factor: 4.668

Review 6.  Considerations for Imaging the Inferior Vena Cava (IVC) with/without IVC Filters.

Authors:  Jessie Aw-Zoretic; Jeremy D Collins
Journal:  Semin Intervent Radiol       Date:  2016-06       Impact factor: 1.513

7.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

Review 8.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

9.  Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.

Authors:  Nadia R Ayat; Jing-Can Qin; Han Cheng; Sarah Roelle; Songqi Gao; Yajuan Li; Zheng-Rong Lu
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

10.  Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.

Authors:  A Adhipatria P Kartamihardja; Takahito Nakajima; Satomi Kameo; Hiroshi Koyama; Yoshito Tsushima
Journal:  Br J Radiol       Date:  2016-07-26       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.